Last reviewed · How we verify
ABP-745 Dose C
ABP-745 Dose C is a Bispecific antibody Small molecule drug developed by Atom Therapeutics Co., Ltd. It is currently in Phase 2 development.
ABP-745 is a bispecific antibody that simultaneously engages two distinct molecular targets to modulate immune or disease-related pathways.
ABP-745 Dose C is not mentioned in the provided facts, but ABP-745 Dose A and ABP-745 Dose B are being studied in a Phase II clinical trial for the treatment of Atherosclerosis, Cardiovascular Disease, and ASCVD. The study is evaluating the efficacy, safety, and pharmacokinetic profile of ABP-745 in patients with Atherosclerosis.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | ABP-745 Dose C |
|---|---|
| Sponsor | Atom Therapeutics Co., Ltd |
| Drug class | Bispecific antibody |
| Modality | Small molecule |
| Phase | Phase 2 |
Mechanism of action
As a bispecific antibody candidate from Atom Therapeutics, ABP-745 is designed to bind two different antigens or receptors simultaneously, enabling dual pathway modulation. This approach may enhance therapeutic efficacy by targeting complementary mechanisms or improving selectivity compared to monospecific antibodies. The specific targets and mechanism remain proprietary pending further clinical disclosure.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABP-745 Dose C CI brief — competitive landscape report
- ABP-745 Dose C updates RSS · CI watch RSS
- Atom Therapeutics Co., Ltd portfolio CI
Frequently asked questions about ABP-745 Dose C
What is ABP-745 Dose C?
How does ABP-745 Dose C work?
Who makes ABP-745 Dose C?
What drug class is ABP-745 Dose C in?
What development phase is ABP-745 Dose C in?
Related
- Drug class: All Bispecific antibody drugs
- Manufacturer: Atom Therapeutics Co., Ltd — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing